Literature DB >> 32310720

Impact of Pharmacy Benefit Managers on Oncology Practices and Patients.

Trevor J Royce1, Caroline Schenkel2, Kelsey Kirkwood2, Laura Levit2, Kathryn Levit3, Sheetal Kircher4.   

Abstract

Pharmacy benefit managers (PBMs) are thoroughly integrated into the drug supply chain as administrators of prescription drug benefits for private insurers, self-insuring business, and government health plans. As the role of PBMs has expanded, their opaque business practices and impact on drug prices have come under increasing scrutiny. PBMs are particularly influential in oncology care because prescription drugs play a major role in the treatment of most cancers and an increasing number of patients with cancer are treated with oral oncology agents managed by PBMs. There is concern that some PBM practices may threaten access to high-quality cancer care and may increase the financial and administrative burden on patients and practices. In this article, we review the role of PBMs in prescription drug coverage and reimbursement, discuss the impact of PBMs on oncology care, and present data from the 2018 ASCO Practice Survey assessing the knowledge and attitude of oncology practices toward PBMs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32310720      PMCID: PMC7351331          DOI: 10.1200/JOP.19.00606

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  27 in total

1.  The ABCs of PBMs.

Authors:  R J Strongin
Journal:  Issue Brief Natl Health Policy Forum       Date:  1999-10-27

2.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.

Authors:  Sonya Blesser Streeter; Lee Schwartzberg; Nadia Husain; Michael Johnsrud
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

3.  Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Nancy L Keating
Journal:  JAMA       Date:  2019-05-28       Impact factor: 56.272

4.  The Rising Price of Cancer Drugs-A New Old Problem?

Authors:  Vinay Prasad; Ruibin Wang; Salma H Afifi; Sham Mailankody
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

5.  Value-Based Physician Payment in Oncology: Public and Private Insurer Initiatives.

Authors:  James C Robinson
Journal:  Milbank Q       Date:  2017-03       Impact factor: 4.911

6.  How Pharmacy Benefit Managers Add to Financial Toxicity: The Copay Accumulator Program.

Authors:  Chadi Nabhan; Eli G Phillips; Bruce A Feinberg
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

7.  Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs.

Authors:  Karen Van Nuys; Geoffrey Joyce; Rocio Ribero; Dana P Goldman
Journal:  JAMA       Date:  2018-03-13       Impact factor: 56.272

Review 8.  American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.

Authors: 
Journal:  J Oncol Pract       Date:  2017-11-01       Impact factor: 3.840

9.  Direct and Indirect Remuneration Fees: The Controversy Continues.

Authors:  Michael Gabay
Journal:  Hosp Pharm       Date:  2017-11-09

10.  Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis.

Authors:  Rinaa S Punglia; Akiko M Saito; Bridget A Neville; Craig C Earle; Jane C Weeks
Journal:  BMJ       Date:  2010-03-02
View more
  1 in total

1.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.